The adjusted mean change in forced vital capacity at week 52 was –107.1 mL in patients given placebo, –61.2 mL in patients treated with 9 mg of nerandomilast twice a day, and –64.9 mL in patients ...

At week 52, 50.9% of patients on elafibranor met the primary endpoint of biochemical response compared with 3.8% of those receiving the placebo. Lower baseline alkaline phosphatase (ALP) levels were ...

The highest levels of immunoglobulin G (IgG), IgM, and IgA were observed in patients with cirrhosis due to autoimmune liver disease, primary biliary cholangitis, and alcoholic liver disease, ...

Researchers developed an AI-based framework that can generate a report like a primary care physician, which can then help identify undiagnosed patients with ATTR-CM and individuals who are at risk of ...

The FDA granted Fast Track Designation to coramitug for ATTR-CM as it advances in the ongoing phase 3 CLEOPATTRA trial. The US Food and Drug Administration (FDA) has granted Fast Track Designation to ...

Best practices most often mentioned by amyloidosis stakeholders included patient-centric multidisciplinary care, responsiveness to patients' questions, and timely intake of new patients who are at ...

The prevalence of irregular red cell alloantibodies was 8.04% in pediatric patients, with anti-E and anti-Mi antibodies the most common. Pediatric patients can develop irregular, non-ABO red cell ...

Sparsentan is believed to help protect the kidneys and reduce damage through a mechanism that targets both endothelin A and angiotensin II receptors. The US Food and Drug Administration (FDA) has ...

In a cross-sectional study, the researchers reported psychiatric comorbidities in 46.5% of 43,270 adults with neurofibromatosis. The most common psychiatric comorbidities included mood disorders (22.1 ...

The high-output heart failure cohort was characterized by an increased frequency of secondary MF and lower baseline hemoglobin levels. Echocardiographic high-output heart failure in patients with ...

Researchers are beginning to investigate the role antibody-microbiota dynamics play in myasthenia gravis (MG). The gut microbiome is a diverse community that evolved alongside the immune system, ...

Lower rates of chronic and acute GVHD, infections, and nonrelapse mortality indicate a substantially reduced toxicity burden. In patients with myelodysplastic syndrome (MDS) and acute leukemias ...